Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability

Core Insights - Invivyd, Inc. announced preliminary financial results for Q4 2024, highlighting significant revenue growth and operational efficiency improvements [1][2][3] Financial Performance - The company reported preliminary Q4 2024 net product revenue of $13.8 million, a 48$9.3 million [3][7] - Total operating costs and expenses for Q4 2024 were approximately $32 million, reflecting a 55$71.6 million [3][7] - Invivyd ended 2024 with $69.3 million in cash and cash equivalents, along with$10.9 million in outstanding accounts receivable [2][7] Profitability Outlook - The company continues to target near-term profitability by the end of the first half of 2025, leveraging existing cash, anticipated revenue growth, and reduced manufacturing expenses [2][7] Product Information - PEMGARDA™ (pemivibart) is an investigational monoclonal antibody designed for pre-exposure prophylaxis against COVID-19, showing in vitro neutralizing activity against major SARS-CoV-2 variants [4][5][11] - VYD2311 is another monoclonal antibody candidate in development, aimed at providing new prophylactic and therapeutic options for COVID-19 [11][12] Regulatory Status - PEMGARDA has received emergency use authorization (EUA) from the U.S. FDA for specific immunocompromised populations, although it is not authorized for treatment or post-exposure prophylaxis of COVID-19 [5][6][10]